Can psychedelics reveal clues about Alzheimer's risk?

NCT ID NCT07386730

First seen Feb 04, 2026 · Last updated May 20, 2026 · Updated 18 times

Summary

This early-stage study looks at how two drugs, psilocybin and dextromethorphan, affect brain activity in healthy adults aged 50-85 who report low well-being. Researchers want to see if these drugs change brain wave patterns and inflammation markers, and whether those changes relate to early signs of Alzheimer's disease. The study does not aim to treat or cure any condition, but to gather knowledge about brain function and Alzheimer's risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANHEDONIA IN HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California San Francisco, Sandler Neuroscience Building

    San Francisco, California, 94158, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.